Early diagnosis of pancreatic adenocarcinoma: role of stroma, surface proteases, and glucose-homeostatic agents
Language English Country United States Media print
Document type Journal Article, Review
PubMed
22695086
DOI
10.1097/mpa.0b013e31823b5827
PII: 00006676-201207000-00001
Knihovny.cz E-resources
- MeSH
- Adenocarcinoma diagnosis metabolism MeSH
- Insulin-Secreting Cells metabolism MeSH
- Early Diagnosis MeSH
- Diabetes Mellitus, Type 2 metabolism MeSH
- Dipeptidyl Peptidase 4 metabolism MeSH
- Endopeptidases MeSH
- Glucagon-Like Peptide 1 metabolism MeSH
- Glucose metabolism MeSH
- Humans MeSH
- Membrane Proteins metabolism MeSH
- Pancreatic Neoplasms diagnosis metabolism MeSH
- Serine Endopeptidases metabolism MeSH
- Gelatinases metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Dipeptidyl Peptidase 4 MeSH
- DPP4 protein, human MeSH Browser
- Endopeptidases MeSH
- fibroblast activation protein alpha MeSH Browser
- Glucagon-Like Peptide 1 MeSH
- Glucose MeSH
- Membrane Proteins MeSH
- Serine Endopeptidases MeSH
- Gelatinases MeSH
OBJECTIVES: New-onset diabetes in pancreatic adenocarcinoma is due to a combination of insulin resistance and decreased β-cell function. Its differentiation from the common type 2 diabetes is the prerequisite for early diagnosis of pancreatic adenocarcinoma. Little attention has been paid to pancreatic stroma and surface proteases. METHODS: The activated fibroblasts selectively express fibroblast activation protein α, a structural homolog of the ubiquitously expressed dipeptidyl peptidase 4. Their role in pancreatic carcinogenesis is reviewed. RESULTS: Homodimers and heterodimers of both enzymes display high specificity for peptides and proteins with penultimate proline or alanine. Most glucose-homeostatic agents are candidate substrates of these enzymes. The biological activity of truncated substrates is decreased or absent. CONCLUSIONS: The interactions of surface proteases with glucose-homeostatic agents may adequately explain the evolution of diabetes associated with pancreatic adenocarcinoma and differentiate it from the common type 2 diabetes.
References provided by Crossref.org
